| RHEUMATO-DERMATOLOGY SYMPOSIUM |
|
| Year : 2019 | Volume
: 3
| Issue : 1 | Page : 18-22 |
|
|
Dermatomyositis: A dermatological perspective
Deepthi Ravi1, Smitha Prabhu2
1 Consultant Dermatologist, Deepthi's Derma Care, Chennai, Tamil Nadu, India
2 Department of Dermatology and Venereology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India
Correspondence Address:
Smitha Prabhu
Department of Dermatology and Venereology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal - 576 104, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/CDR.CDR_46_18
|
|
|
Dermatomyositis (DM) is an autoimmune idiopathic inflammatory myopathy which has distinctive skin lesions, specific autoantibodies, and most importantly, symmetrical proximal muscle weakness and muscle inflammation of subacute onset. Some cases of DM present with only characteristic skin lesions without muscle disease and referred to as clinically amyopathic DM. Characteristic skin lesions include violaceous discoloration around the eyelids (heliotrope rash), erythematous rash over the face, erythematous scaly papules over the interphalangeal and metacarpophalangeal joints (Gottron's papules), erythema over the same joints (Gottron's sign), photosensitive pruritic erythema over the anterior chest and neck (V-sign), erythema extending to the shoulders and back (Shawl sign), distorted cuticles with dilated capillary loops over the proximal nail folds, and hyperkeratotic fissured skin over the palms and lateral aspect of the fingers (Mechanic's hands). Causes for mortality and morbidity in DM include malignancy, respiratory disease, and cardiac disease. After ruling out internal associations, Mangement involves photoprotection and medications including systemic corticosteroids, antimalarials, mycofenolate mofetil, biologicals and IV immunoglobulins, depending upon patient parameters.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
